OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations

Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints. NEW YORK, June 2, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23.4% of their holdings in a single session after the company revealed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema.